• Source: Phil S. Baran

Phil S. Baran (born August 10, 1977) is a synthetic organic chemist and Professor in the Department of Chemistry at the Scripps Research Institute. His work is focused on synthesizing complex natural products, the development of new reaction methodologies within synthetic organic electrochemistry, and the development of new reagents. He holds several patents and has authored nearly 300 research articles.




Early life and education


Phil S. Baran was born in Denville, New Jersey, on August 10, 1977, and grew up in Coral Springs, Florida. He remembers being a poor student at high school, preferring to play role-playing games, write computer programs and build with Lego.
Encouraged by his chemistry teacher to experiment after school, Baran quickly channeled his creativity into crafting molecules. In 1995 he began a chemistry degree at New York University, and enthusiastically accepted [David] Schuster’s offer to work in his lab, synthesizing compounds that linked C60 with porphyrins to make artificial photosynthetic systems. He received his BS in chemistry from New York University in 1997.
He went on to earn his PhD from The Scripps Research Institute in 2001, under the supervision of K. C. Nicolaou, an experience he recalls was 'like hardcore Navy Seal training' and where he co-authored 30 papers in less than four years.
He then pursued a postdoctoral fellowship in the laboratory of Nobel Laureate Elias James Corey at Harvard University who reflected on Baran's time in his lab, saying, "He had a phenomenal grasp of synthetic chemistry," and "felt that he could be a leader in his generation."




Independent academic career



Phil Baran began his independent career at the Scripps Research Institute in the summer of 2003, at only 26 years old, and received tenure just three years later. In the 20 years since then, he has supervised over 300 graduate students, post-doctoral scholars, visiting scholars and interns. He is currently the Dr. Richard A. Lerner Endowed Chair at Scripps Research
His work is focused on practicality and simplicity in the total synthesis of organic molecules, eschewing protecting groups, functional group manipulations, and non-essential redox manipulations. Several of his total syntheses are now being adopted for commercial production. His contributions in methodology center around practical C-H functionalization reactions and have had a remarkable impact based on actual drug candidates brought into the clinic using these methods and the sales of numerous reagents he has commercialized for use in the pharmaceutical industry. Additionally, since the mid 2010's, Baran's lab has focused on developing electrochemical methodologies for use in total synthesis and medicinal chemistry as it allows for more atom economical and environmentally-conscious protocols.
Phil Baran has given hundreds of talks all over the world and is the recipient of dozens of distinguished awards. Among many honors, he has notably earned the Amgen Young Investigator Award (2005), ACS Award in Pure Chemistry (2010), the MacArthur Fellowship (2013), the Mukaiyama Award (2014), the ACS Elias J. Corey Award (2016), the Danisco Science Excellence Medal Award (2022), and the Edison Patent Award (2023).




Industry career and collaborations


In addition to his numerous achievements in academia, Baran also holds many accolades in industry as a scientific entrepreneur, company co-founder, consultant and scientific advisor. He co-founded his first company Sirenas Marine Discovery in 2012 alongside Eduardo Esquenazi and Jake Beverage —a company that is dedicated to marine-inspired molecular discoveries and pre-clinical leads for cancer, HIV, and infectious diseases. In 2016, he joined forces with fellow Scripps colleagues, Benjamin F. Cravatt and Jin-Quan Yu to co-found Vividion Therapeutics with the goal of identifying small molecules that bind currently undrugged targets via a covalent-first chemoproteomics approach. Vividion was sold to Bayer in 2021 for $2 billion ($1.5 billion with an additional $500 million in milestone payments). In the same year, Baran founded Elsie Biotechnologies, an antisense oligonucleotide (ASO)-based company with the goal of discovering therapeutic agents that can achieve desirable medicinal effects not attainable with existing drugs by modulating gene expression of DNA or RNA. Elsie Biotechnologies was sold to GlaxoSmithKline (GSK) in 2024 for $50 million. Baran also co-founded and is on the scientific advisory team of Galileo Biosystems, a preclinical stage biopharmaceutical company focused on developing therapeutic agents for inflammatory and autoimmune diseases. He also serves on the scientific advisory board for seven additional companies (Eisai, Kemxtree, Quanta Therapeutics, Inc., Alkermes, Inc, Nutcracker Therapeutics, Inc., Hongene Biotech Corporation, and Sage Therapeutics) and has consulted for over twenty more, including presently at Bristol-Meyers-Squibb, Gilead, and BASF Corporation.

In 2014, Baran began a partnership with IKA, well-known laboratory equipment manufacturer, to bring to market a revolutionary piece of equipment that promised to standardize electrochemical protocols and make electrochemistry accessible to the average organic chemist. Three years after the partnership began, the ElectraSyn was debuted in a Steve Jobs-esque fashion at the American Chemical Society annual meeting, drawing a large crowd of eager chemists. In the seven years since, the ElectraSyn and subsequent ElectraSyn 2.0 have been widely adopted into the synthetic community and utilized towards hundreds of research articles and patents. The publicity surrounding Baran's (as well as Jin-Quan Yu's) partnership with IKA was highlighted with a memorable promotional video found here.




Total syntheses


Dragocins A−C (2024)
Dynobactin A (2024)
(−)-Cyclopamine (2023)
(+)-KB343 (2023)
Portimine A and B (2023)
Kibdelomycin (2022)
Darobactin A (2022)
(+)-Calcipotriol (2022)
Tagetitoxin (2020)
(–)-Maximiscin (2020)
Taxol (2020)
Teleocidins B-1-B-4 (2019)
Herqulines B and C (2019)
(–)-Thapsigargin (2017)
Ariaosamines (2016)
(–)-Maoecrystal V (2016)
Pallambins C and D (2016)
(+)-Phorbol (2016)
Verruculogen (2015)
Fumitremorgin A (2015)
Ouabagenin (2013, 2015)
Dixiamycin B (2014)
(+)-Ingenol (2014)
(–)-Taxuyunnanine (2014)
(+)-Hongoquercin A (2013)
Phellodonin (2013)
Sarcodonin (2013)
Pipercyclobutanamide A (2012)
(+)-Taxadienone (2011)
(+)-Psychotetramine (2011)
(–)-Palau’amine (2010)
Vinigrol (2009)
(±)-Massadine (2008)
(±)-Psychotrimine (2008)
Cortistatin A (2008)
(–)-Axinellamine A and B (2008)
(±)-Chartelline C (2006)
Haouamine A (2006)
Avrainvillamide (2005)
Stephacidin A (2005)
Sceptrin (2004)




Publications


Phil S. Baran has authored and co-authored nearly 300 research publications and has an h-index of 126 with over 50,000 citations across his group's publications. Articles author by Baran and his group can be found in numerous prestigious journals including Science, Nature, Journal of American Chemical Society (JACS), Angewandte Chemie, Journal of Organic Chemistry (JOC), among several others.
Baran co-wrote the digital interactive reference text The Portable Chemist’s Consultant: A Survival Guide for Discovery, Process, and Radiolabeling as well as several book chapters and forewords.




Community engagement


Reddit AMA, 2016
"What Makes a Good Chemist"




Awards and honors


Highly Cited Researcher, yearly, 2014–2024
Edison Patent Award, 2023
Horizon Discovery Prize, Royal Society of Chemistry, 2022
Danisco Science Excellence Medal Award, 2022
Bristol Chemical Synthesis Syngenta Award, 2021
Janssen Prize for Creativity, 2020
Inhoffen Medal, 2019
Manchot Research Professorship, 2017
Member, The National Academy of Sciences, 2017
Emanuel Merck Lectureship, 2017
Mukaiyama Award, 2014
MacArthur Fellowship, 2013
Royal Society of Chemistry Synthetic Organic Chemistry Award, 2013
ACS San Diego Section Distinguished Scientist Award, 2012
ISHC Katritzky Heterocyclic Chemistry Award, 2011
Thieme–IUPAC Prize in Synthetic Organic Chemistry, 2010
ACS Award in Pure Chemistry, 2010
Sackler Prize, 2009
Novartis Lecturer, 2007–2008
Hirata Gold Medal, 2007
National Fresenius Award, 2007
Pfizer Award for Creativity in Organic Chemistry, 2006
Beckman Young Investigators Award, 2006
Alfred P. Sloan Foundation Fellow, 2006–2008
BMS Unrestricted "Freedom to Discover" Grant, 2006–2010
NSF Career, 2006–2010
Eli-Lilly Young Investigator Award, 2005–2006
AstraZeneca Excellence in Chemistry Award, 2005
DuPont Young Professor Award, 2005
Roche Excellence in Chemistry Award, 2005
Amgen Young Investigator Award, 2005
Searle Scholar Award, 2005
GlaxoSmithKline Chemistry Scholar Award, 2005–2006
Nobel Laureate Signature Award for Graduate Education in Chemistry, ACS, 2003
National Institutes of Health Post-Doctoral Fellowship Award, Harvard, 2001–2003
Hoffmann-La Roche Award for Excellence in Organic Chemistry, 2000
Lesly Starr Shelton Award for Excellence in Chemistry Graduate Studies, 2000
National Science Foundation Pre-Doctoral Fellowship Award, Scripps, 1998–2001




References






External links


Phil Baran: Molecule Magician, The Scientist Magazine
The sultan of synthesis, Chemistry World, Royal Society of Chemistry
Evolution from Academia to Industry – Interview with Professor Phil S. Baran, Oxbridge Biotech Roundtable

Kata Kunci Pencarian:

• Sikloadisi
• Bermuda Bowl
• Daftar ekonom
• Teen Choice Awards 2014
• Film di tahun 2016
• Lucent
• Phil S. Baran
• Baran (name)
• Scripps Research
• Cycloaddition
• Total synthesis
• K. C. Nicolaou
• List of chemists
• List of American Academy of Arts and Sciences members (2006–2019)
• Paclitaxel total synthesis
• ACS Award in Pure Chemistry